A view from the Center

>

Deloitte's Life Sciences & Health Care Blog

Filter by category or month:

Before moving data to the cloud, health organizations should assess benefits and risks

by Jeffrey Winn and Justin Rowe, Cyber Risk Services, Deloitte & Touche LLP

A growing number of health care organizations expect to move their electronic health records (EHRs) to the cloud.1 Migrating EHRs and other data to the cloud could make it easier for these organizations to build and use next-generation solutions such as big data analytics, population health, digital health, and use of the internet of things (IoT) to keep pace with future trends.

Read more

The future of health could be ‘udderly’ amazing

by Steve Davis, Deloitte Center for Health Solutions

When it comes to the future of health, it seems that cows (yes, cows!) might be a couple hoof-steps ahead of people. While visiting relatives in Ireland last month, we stopped at a small dairy farm about 90 miles outside of Belfast. What I saw in the barn that afternoon lines up surprisingly well with Deloitte’s vision for the future of health where always-on sensors detect potential health problems long before symptoms surface.

Read more

For health plans, next-gen workers may be just as critical as next-gen technology

by Eileen Schreiber Radis, Deloitte Consulting LLP, and Nigel Lennox Ferguson, Deloitte Consulting LLP

Many health plans are investing in next-generation technologies, but they might not yet have a strategy for building a next-generation workforce. The nature of work in changing in health and in all industries. This is being driven by automation and technology as well as increased consumerism, generational shifts, and open talent models. We expect the future of work will impact every health plan employee.

Read more

The global future of health: Are the challenges facing countries as unique as quokkas?

by David Betts, Principal, Deloitte Consulting LLP

During a recent visit to Australia, I had the opportunity to visit Rottnest Island, which lies off the western coast. This island is fascinating to me for many reasons. For example, it is the only place in the world where you’ll encounter quokkas—small marsupials that look like a cross between a house cat and a small kangaroo.1 Quokkas being unique to this island got me thinking about what being unique really means.

Read more

With drug rebates on the chopping block, stakeholders should prepare for change

by George Van Antwerp, Managing Director, Deloitte Consulting LLP

Early this year, the US Department of Health and Human Services (HHS) proposed eliminating safe-harbor protections for the rebates drug manufacturers pay to pharmacy benefit managers (PBMs), Medicare Part D plans, and Medicaid managed care organizations. At the same time, HHS proposed two new safe-harbor protections for some point-of-sale (POS) price reductions on prescription drugs and certain PBM service fees.

Read more

Digital tech and strong patient-advocacy partnerships could be a win-win-win for pharma, advocacy groups, and patients

by Jonathan Fox, Specialist leader, Deloitte Consulting LLP

I’m in Philadelphia this week for the annual EyeForPharma conference where I’ll be moderating a panel looking into how pharmaceutical companies and advocacy groups can take their relationship to the next level. Both sides have something to gain, and the patient could be the biggest winner.

Pharmaceutical companies often collaborate with patient advocacy groups,

Read more